Company Profile
Summit Therapeutics Stock Price, News & Catalysts
- Ticker:
- SMMT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United Kingdom with U
Stock performance
16.69 USD (-1.30%)
Close
Last updated: October 1, 2026
11.5B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, SMMT closed down 1.30% at $16.69. No new same-company headline was identified in the current news window.
Company overview
Oncology-Focused Biopharmaceutical Company
Summit Therapeutics is building an oncology business around ivonescimab, a bispecific antibody designed to inhibit both PD-1 and VEGF. The company holds development and commercialization rights in the United States, Canada, Europe, Japan, and selected other territories through its partnership with Akeso.
Dual PD-1 and VEGF Mechanism
Ivonescimab combines immune-checkpoint blockade with anti-angiogenic activity in a single molecule. Its tetravalent design is intended to concentrate VEGF inhibition in the tumor microenvironment while preserving the antitumor immune activity associated with PD-1 blockade.
Broad Lung Cancer Program
The development program spans EGFR-mutated non-small cell lung cancer after tyrosine kinase inhibitor therapy and first-line squamous and nonsquamous disease. Multiple global Phase 3 studies are evaluating ivonescimab with chemotherapy or as part of other treatment combinations.
Expansion Across Solid Tumors
Summit is exploring ivonescimab beyond lung cancer through external combination studies and additional tumor types, including colorectal and head and neck cancers. Collaborations with other oncology companies provide access to complementary mechanisms without requiring Summit to internally own every combination asset.
Partner-Enabled Global Development
Akeso retains rights in China and other licensed territories and provides an extensive clinical dataset from its own studies. Summit uses those data, together with global trials conducted under its rights, to support regulatory submissions and commercial planning in major Western markets.
Future catalysts
- FDA PDUFA decision for ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer on November 14, 2026.
- Final progression-free-survival analysis and interim overall-survival analysis from the squamous HARMONi-3 cohort in the second half of 2026.
- Progression-free-survival and interim overall-survival analyses from the nonsquamous HARMONi-3 cohort in the first half of 2027.
- Initial data from the Arcus-sponsored ivonescimab combination study around mid-2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Summit Therapeutics (SMMT)?
Summit Therapeutics (SMMT) most recently closed at 16.69 USD, a -1.30% move versus the previous session.
What is the market cap of Summit Therapeutics (SMMT)?
Summit Therapeutics currently has a market capitalization of 11.5B USD on BioPharmSignal.
What does Summit Therapeutics do?
Oncology-Focused Biopharmaceutical Company Summit Therapeutics is building an oncology business around ivonescimab, a bispecific antibody designed to inhibit both PD-1 and VEGF. The company holds development and commercialization rights in the United States, Canada, Europe, Japan, and selected other territories through its partnership with Akeso. Dual PD-1...
On which exchange is SMMT stock listed?
Summit Therapeutics (SMMT) is associated with NASDAQ, United Kingdom with U, Biopharma.
What is PD-1?
Oncology-Focused Biopharmaceutical Company Summit Therapeutics is building an oncology business around ivonescimab, a bispecific antibody designed to inhibit both PD-1 and VEGF.
Which conditions is Summit Therapeutics targeting with PD-1?
Summit Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Summit Therapeutics describe recent progress with PD-1?
FDA PDUFA decision for ivonescimab plus chemotherapy in EGFR-mutated non-small cell lung cancer on November 14, 2026. Final progression-free-survival analysis and interim overall-survival analysis from the squamous HARMONi-3 cohort in the second half of 2026. Progression-free-survival and interim overall-survival analyses from the nonsquamous HARMONi-3...
What is ivonescimab?
Oncology-Focused Biopharmaceutical Company Summit Therapeutics is building an oncology business around ivonescimab, a bispecific antibody designed to inhibit both PD-1 and VEGF.